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Background: We report here a new type of protein chip to detect antibodies in sera. This chip method was used
to a prototype created to detect hepatocellular carcinoma (HCC) -related autoantibodies in the sera of hepatitis C
virus (HCV) infected individuals.
Results: Five cysteine-tagged (Cys-tag) and green fluorescent protein (GFP)-fused recombinant heat shock protein
70 (HSP70), superoxide dismutase 2 (SOD2), and peroxiredoxin 6 (PRDX6), were spotted and immobilized on
maleimide-incorporated diamond-like carbon (DLC) substrates. The antibodies in diluted sera were trapped by these
proteins at each spot on the chip, and visualized by a fluorescence-conjugated anti-human IgG. The total
immobilized protein level of each spot was detected with anti-GFP mouse IgG and a fluorescence-conjugated
secondary anti-mouse IgG. The ratio between the two fluorescence intensities was used to quantify autoantibody
levels in each serum sample. Heat treatment of the chip in a solution of denaturing and reducing agents, before
serum-incubation, improved autoantibody detection. We tested serum samples from healthy individuals and HCC
patients using the chips. The HSP70 autoantibodies were found at high levels in sera from HCV-positive HCC
patients, but not in HCV-negative sera.
Conclusion: This protein chip system may have useful properties to capture a specific set of antibodies for
predicting the onset of particular cancers such as HCC in HCV-infected individuals.
Keywords: Antigen chip, Antibody profiling, Cysteine-tag, Maleimide, Hepatitis C virus, Hepatocellular carcinoma,
Tumor-associated antigen, AutoantibodyBackground
Hepatitis C virus (HCV) infection causes chronic hepa-
titis, liver cirrhosis, and hepatocellular carcinoma (HCC),
which is one of the most malignant tumors and a global
concern especially throughout Asia and Africa [1,2]. To
avoid progression to HCC, HCV infected individuals must
be monitored carefully. Biomarkers are needed for the* Correspondence: nakamura@yamaguchi-u.ac.jp
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reproduction in any medium, provided the orearly detection and monitoring of HCC. Alpha-fetoprotein
(AFP) is a common biomarker for the diagnosis of HCC,
but it is not always sufficiently sensitive to detect very early
stages of HCC. Serum autoantibodies against tumor-
associated antigen (TAA) offers an alternative to AFP [3,4].
Discovery of TAA has been tried mainly by three
methods which differ in the method used to trap autoanti-
bodies in sera [5]. The first is SEREX (SErological identifi-
cation of antigens by Recombinant EXpression cloning),
the second is SERPA (SERological Proteome Analysis) [6]
or PROTEOMEX (a combination of PROTEOMics and
SEREX) [7], recently, the third method, proteome-coveredtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Autoantibody detection on chip. (A) Autoantibody
detection procedures. Protein chips were immersed in SDS/2ME
sample buffer and heated at 95°C for 5 min (Immunodetection step
1) and washed (step 2). The chips were blocked with BSA (step 3),
incubated with diluted serum (step 4) or mouse anti-GFP
monoclonal IgG (step 5), washed (step 6), incubated with
AlexaFluora 633 (Alexa633)-conjugated anti-human IgG to quantify
bound serum autoantibodies (step 7), incubated with AlexaFluore
555 (Alexa555)-conjugated anti-mouse IgG antibody to quantify the
amount of GFP-tagged protein (step 8), and washed (step 9). The
chips were examined for Alexa555 and Alexa633 fluorescence of the
same spot in the same chip and Alexa633 fluorescence of each spot
was normalized using Alexa555 fluorescence of the same spot (step
10).(B-C) Schema of predicted protein chip surface before step 1 (B)
and after step 9 (C). 6H: 6xHis-tag, 5C: 5xCys-tag.
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been developed [8-10]. Although several TAAs have been
found using more than one of these methods, no reported
TAAs show high sensitivity and specificity to detect HCC
in patient sera [11-18]. As a result, combination of infor-
mation from multiple autoantibodies possibly increases
the HCC detection sensitivity and specificity. Such kind of
diagnostic parallel detection has been attempted using
several assay systems, including polystyrene microarrays,
slot blot on nitrocellulose membranes, and microarrays
on sol-gel derived materials [19-21].
Here, we describe a new chip-based system for the
detection of multiple autoantibodies in sera from HCC
patients. Model antigenic proteins to test this prototype
chip system were HSP70, SOD2 and PRDX2. These
three HCV-related HCC TAAs were selected from a
PROTEOMEX study using the sera of Japanese HCC pa-
tients by our group, and have also been reported by others
[17,18]. Using the characteristic properties of cysteine
[22], cysteine-tagged recombinant antigenic proteins were
immobilized on maleimide-coated diamond-like carbon
(DLC)-coated silicon chips by the covalent bond between
cysteine sulfhydryl and maleimide residues [23]. Theore-
tically, cysteine-tagged proteins on this chip were floating
in surrounding solution attached to the chip substrate
only at the C-terminus (Figure 1B and C), which is diffe-
rent from proteins bound on conventional nitrocellulose
membrane via hydrophobic residues throughout the pro-
teins. This small, hard, DLC silicon chip is stable to heat,
is easy to hand for the washing process, provides sensitive
detection of antibodies in low backgrounds, and is capable
of high-throughput screening of sera. We constructed a
procedure for the detection and quantification of anti-
bodies bound on a cysteine-tagged protein array via
maleimide residues on a DLC silicon chip. HSP70 anti-
bodies were highly detectable in this protein chip sys-
tem among HCC patient and HCV infected individual.
Results
Fabrication of antigenic protein array chips
Recombinant antigenic proteins of HSP70, SOD2 and
PRDX6 were produced in E. coli BL21 strain. All proteins
were constructed to contain a six-histidine (6xHis)-fused
GFP-tag (26 kDa) at the N-terminus and a 5×Cys-tag at
the C-terminus. A 6×His-GFP-5×Cys construct with no
fusion partner (31 kDa) was used as a control. The N-
terminal portion of HSP70 (HSP70N; 42 kDa) containing
the ATPase domain and C-terminal portion (HSP70C;
29 kDa) containing the substrate-binding domain were
expressed separately. SOD2 (22 kDa) and PRDX6
(25 kDa) were expressed as whole proteins.
The expression of recombinant GFP-tagged antigenic
proteins were confirmed by SDS-PAGE after purification
using Ni-affinity gel (Figure 2A). The proteins were
Figure 2 The first-designed HCV-related HCC patient autoantigen protein chip. (A) The five recombinant proteins confirmed by SDS-PAGE.
The proteins were 6×His-GFP-5×Cys (G), 6×His-GFP-HSP70-C-terminal domain-5×Cys (HC), 6×His-GFP-HSP70-N-terminal domain-5×Cys (HN), 6×
His-GFP-SOD2-5×Cys (S), and 6×His-GFP-PRDX6-5×Cys (P). (B-G) The first-designed protein chip and its certification. (B) GFP fluorescence from the
protein chip as detected by fluorescence microscopy. The proteins (128 fmol per spot) were covalently cross-linked to maleimide-incorporated
diamond-like carbon chip. Spots were 200 μm in diameter. Abbreviations for proteins are same as in A. (C-G) Full color fluorescence images of
immobilized protein by ProscanArray. The protein chips were detected after denaturation and incubation of primary anti-His antibody (C), anti-GFP (D),
anti-HSP70 (E), anti-SOD2 (F), and anti-PRDX6 (G), visualized using fluorescent secondary antibodies.
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10 nL, 200 μm spots containing 128 fmol protein each.
The amount of antigenic proteins on each chip was veri-
fied by measuring GFP fluorescence with a fluorescent
microscope (Figure 2B), and representative chips were
validated by fluorescent immunodetection using specific
antibodies against 6×His (Figure 2C), GFP (Figure 2D),
HSP70C (Figure 2E), SOD2 (Figure 2F), or PRDX6
(Figure 2G), visualized fluorescent secondary antibodies.
HSP70N (lane HN in Figure 2B) was not detected by poly-
clonal antibodies against HSP70 on this first-designed chip
(Figure 2E), suggesting that the ATPase domain of HSP70,
a functionally important conserved domain, could not be
recognized by commercially available antibodies on this
chip.
Effect of denaturing antigenic proteins immobilized on
chips
GFP fluorescence shows basically the amount of antigenic
proteins on a chip. The protein amount in each spot is es-
sential for quantification of autoantibodies which specifi-
cally bind to the immobilized antigenic proteins. The GFP
fluorescence varied among those antigenic proteins and
some of them showed aggregation on the chip (Figure 2B).
This aggregation was eliminated by denaturing antigenic
proteins on the chip by heating in sodium dodecyl sulfate/
2-mercaptoethanol (SDS/2ME) solution. The antigenic
proteins were then visualized by immunodetection with a
monoclonal anti-GFP mouse IgG antibody followed by
Alexa555-labeled anti-mouse IgG antibody (Figure 1).
This indirect detection of the GFP part in fusion antigenic
proteins improved the ability to detect the antigenicproteins on chips, compared to GFP fluorescence (com-
pare Figure 2D vs. 2B), or immunodetection using anti-6
×His antibody (compare Figure 2D vs. 2C). A protocol for
quantitation of autoantibodies which specifically bound to
denatured antigenic proteins on chips is summarized as in
Figure 1. Briefly, protein chips were first denatured (as
Immunodetection step 1, Figure 1), then chips were
blocked with BSA (step 3), incubated with serum (step 4),
followed by incubation with mouse anti-GFP monoclonal
IgG (step 5). Antibodies were visualized by Alexa Fluora
633 (Alexa633)-conjugated anti-human IgG to visualize
serum autoantibodies bound to antigen spots on the chip
(step 7), followed by Alexa Fluora 555 (Alexa555)-conju-
gated anti-mouse IgG for GFP-tagged proteins (step 8). A
fluorescent microscope and a microarray reader were used
for detection of Alexa555 and Alexa633 fluorescence, and
the Alexa633 fluorescence (antibody binding signal) was
normalized on Alexa555 fluorescence (amount of chip-
bound antigen protein) for each spot (step 10). The fluor-
escence emitted by the chips proved to be quite stable and
repeated measurements could be taken.
To check the effect of the heat-denaturing step in this
protocol, GFP fluorescence was checked at each step by
fluorescent microscopy. GFP fluorescence disappeared
after treatment with SDS/2ME (Figure 3, lower line). In
addition, Alexa555 fluorescence from the GFP tag in-
creased for all protein spots. Alexa633 fluorescence from
HSP70C remained the same, but the background was
lower (Figure 3, lower line) than on non-denatured chips
(Figure 3, upper line). Figure 4 shows Alexa555 fluores-
cence from the GFP tag and Alexa633 fluorescence from
human IgG for each spot using denatured or non-
Figure 3 Effect of pre-treatment for autoantibody detection on chip. Shown are GFP fluorescence images from a non-pre-treated chip
(upper row) and a SDS/2ME/heat pre-treated chip (lower row) incubated with serum no. 150. Shown are fluorescence microscopic images before
(prior to step 1 in Figure 1) and after pre-treatment (after step 2) and following incubation with serum (step 10). The Alexa555 images taken at
step 10 show the total amount of protein bound to the plate, and the Alexa633 images show the amount of serum autoantibodies present
against the C-terminus of HSP70 (HC). Pre-treatment with SDS/2ME improved the Alexa555 signal and reduced the Alexa633 background.
Abbreviations for proteins are same as Figure 2.
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tection of HSP70 using serum No. 193 showed that the
denaturation (bold line in Figure 4) increased the linearity
between Alexa555 and Alexa633 fluorescence compared
to non-denatured chips (dotted line in Figure 4). It was
observed that the GFP left-over fluorescence in some
spots in the non-denatured chip could hardly be detected
by the GFP antibody signal, and it caused lower detection
in Alexa555 GFP cannels, but not Alexa633 autoantibodyFigure 4 Improvement of correlation between dual signals by
SDS/2ME/heat pre-treatment. Alexa555 fluorescence is plotted vs.
Alexa633 fluorescence for each spot for chips spotted with HSP70C
and pre-treated with SDS/2ME/heat (closed circles and bold line) or
not pre-treated (open circles and dotted line) before incubating with
serum no. 193. Each graph contains sixty spots from 10 chips for
four different experiments. R2 values were determined by linear
regression analysis. Detection of HSP70C was enhanced by
pre-treatment with SDS/2ME/heat.cannels. Carrying out denaturation as the first step mainly
improved the quantitation of the GFP-tagged antigenic
proteins by GFP antibody, and this in turn improved the
specific quantitation of autoantibodies, which bind to the
antigenic parts of the same proteins on the chips (Figures 3
and 4).Detection of autoantibodies specific for HCC antigenic
proteins
Using these protein chips and the improved detection
protocol, 31 sera from four test groups were tested, in-
cluding: 6 healthy individuals (“Healthy” in Figure 5), 8
subjects that were negative for both HCV and HCC, but
having some other disease (HCV-/HCC-), 13 subjects
that were positive for HCV and HCC (HCV+/HCC+),
and 4 subjects that were positive for HCV, but negative
for HCC (HCV+/HCC-). Chips incubated with sera from
healthy individuals and HCV-/HCC- subjects had low
antibody levels as indicated by low Alexa633 fluores-
cence despite strong Alexa555 fluorescence (indicating
effective immobilization of GFP-tagged protein). The
Alexa633/555 ratios of these negative control chips were
below 0.8 (Figure 5, upper row). Chips incubated in sera
from HCV+/HCC + subjects had high Alexa633 flores-
cence for some antigen spots. The level of Alexa555 fluo-
rescence was constant for all spots, and the Alexa633/555
ratio for the positive spots was very high (above 0.8) in
four sera from HCV+/HCC + subjects (Serum No. 150,
193, 222c, 419, middle row in Figure 5), and one serum
from HCV+/HCC- group (serum No. 259, bottom row in
Figure 5). Thus, the protein chips could detect elevated
autoantibody levels in several sera from 13 HCV+/HCC +
and HCV+/HCC- subjects (Figure 5).
Figure 5 Quantification of autoantibodies in human serum samples by the first HCC antigen protein chip. Sera from 6 healthy
individuals (Healthy), 8 HCV-/HCC- subjects, 13 HCV+/HCC+, and 4 HCV+/HCC- subjects were tested using the first designed protein chip. Each
column shows the average with standard error bar of the ratio amount (Alexa633/555) of autoantibodies detected for five or six spots of GFP,
GFP-HSP70-C-terminus, GFP-HSP70-N-terminus, GFP-SOD2, GFP-PRDX6 (from left to right) using one chip for each serum (showing examples in
the third row of the box).
Akada et al. Proteome Science 2013, 11:33 Page 5 of 10
http://www.proteomesci.com/content/11/1/33Unexpectedly, we found that many HCC antigen-
positive patient sera reacted with GFP in Figure 5 (espe-
cially high in serum No. 193, 222c, 419). Because all
antigen proteins on the chip were fused proteins with
GFP, it could not be distinguished if the elevated anti-
body levels in these sera came from the recombinant
antigen protein part or the GFP part of the fused pro-
teins on the chip. To overcome this problem, the pro-
tein immobilization time was modified from overnight
to shorter time periods with second-designed chip. It
was found that the 1-hr immobilization was sufficient
for the clear detection of immobilized proteins by spe-
cific antibodies (Figure 6A-D). The second chip was bet-
ter in terms of the HSP70 antibody, because not only
HSP70C spots were detected but also HSP70N spots
were detected slightly (Figure 6B), which was not observed
in the first chip (Figure 2E). We tested the second protein
chip for the same HCC patient sera and controls
(Figure 6E-L). Non-specific GFP detection in some tested
HCC sera still remained slightly (Figure 6I, J and L three
spots in the bottom row (G) on each chip). To see the sig-
nificance of autoantibody detection compared with the
GFP detection, we created a new quantification method.
The new method is to utilize mouse or human non-
immune purified IgG protein on the same chip (m or h,
respectively in Figure 6A-L). Assuming that secondary
antibodies against mouse IgG spot and those against hu-
man IgG gave the same intensity, the percentage of
autoantibody signal per total protein signal monitored
by GFP antibody was calculated. This quantification
method allowed the use of any PMT gain image of twocolors for the same chip by normalization using mouse
and human IgG spots (Figure 6M). Non-specific IgG
binding to GFP in the same patient sera, serum No.
193, 222c, and 419, was lower than it by the previous
chip (Figure 6M vs. Figure 5). In this quantification,
each autoantibody signal of a serum sample was com-
pared with its GFP signal as the statistical control. PRDX6
were not significant in any serum in Figure 6M, but
HSP70C was significant among all five patient sera tested
here.
Furthermore, the detection procedure was modified by
adjusting the fold of serum dilution (×10) and GFP
antibody dilution (x5000) using the third-designed chip.
Re-detection of four tested sera in Figure 5 is shown in
Figure 7A-D. Negative sera in Figure 5 (serum No. 244
of HCV-/HCC- patient having some other disease)
showed the same negative detection (Figure 7A), serum
No. 150 and 164 increased the HSP70C detection
(Figure 7B and 7D), and No. 158 was slightly positive for
HSP70N (Figure 7C). Four newly tested representative
HSP70C positive sera, three HCV/HCC (+/+) sera and
an HCV/HCC (+/−) serum, are shown in Figure 7E-H.
Quantitative analysis of autoantibodies on the third chip
showed increased detection of autoantibodies and statis-
tical significance compared with GFP non-specific detec-
tion (Figure 7I). SOD2 detection was not significant in
the third chip (No. 150 in Figures 6M and 7I). PRDX6
detection was not significant except for one serum (serum
643, Figure 7H and I). It became apparent that HSP70C
auto-antibody was highly significant among HCV-positive
individual and/or HCC patient sera tested.
Figure 6 Autoantibody detection by the second-designed protein chip, to which, 1 hr-incubation was applied for the cross-linking of
antigen proteins. (A-L) Full color fluorescence images of the chips by GenePi×4000B. Detected channel for Alexa555 or Alexa633 are indicated
in left bottom of each figure. The abbreviations are same as for the first protein chip in Figure 2. Additionally, in the top row, two 64 fmol-spots
of mouse IgG (m, detected in A, C and G), rabbit IgG (r, in B and D), and human IgG (h, in E-F, H-L) were immobilized for the secondary
antibody detection control. (A-D) The protein spots certification. After denaturation step, the spots were detected by anti-GFP antibody and
following anti-mouse IgG-Alexa633 secondary antibodies (A), anti-HSP70 and anti-rabbit IgG-Alexa555 (B), anti-SOD2 and anti-mouse IgG-
Alexa633 (C), anti-PRDX6 and anti-rabbit IgG-Alexa555 (D). (E-L) Autoantibody detection on the chips. Autoandibody mode by ×5 diluted sera
and anti-human IgG-Alexa633 (E-F, H-L), or total protein mode by anti-GFP antibody and anti-mouse-Alexa555 (G only) on the same chip of F.
Chip images of the anti-human IgG antibody only (E), or six serum samples tested in Figure 5, C7 (F and G), No.150 (H), No. 193 (I), No. 222c (J),
No. 419 (K), and No. 259 (L) are shown. (M) Quantitative results of the chips. Autoantibodies/ spot (%) in the y-axis is showing percentage of
proteins on each spot bound to autoantibody for sera, calculated after normalization of each signal mode by human IgG and mouse IgG control
spots. Statistical significance of the detection from each GFP-fused recombinant antigen protein was compared with that from GFP on the same
chip by the same sera, shown as *** < 0.0001, 0.0001 < ** < 0.001, 0.001 < * <0.01 by Student-t test. (h), (+/+), (+/−) indicates serum samples from
healthy individuals, HCV+/HCC + patients, HCV+/HCC- individuals, respectively.
Akada et al. Proteome Science 2013, 11:33 Page 6 of 10
http://www.proteomesci.com/content/11/1/33Discussion
Autoantibodies in HCV-HCC patient sera were detected
using four kinds of recombinant GFP-tagged antigenic
proteins, HSP70C, HSP70N, SOD2 and PRDX6, whichwere immobilized by coupling of the cysteine tag at their
C-terminus with maleimide groups on DLC chips. Auto-
antibodies specific for HSP70, SOD2, and PRDX6 in sera
could be quantified by determination of intensity ratios
Figure 7 Autoantibodies detection by the third-designed protein chip. (A-H) Full color autoantibody-detected images by ×10 diluted sera
and anti-human IgG-Alexa633. The representative chip images from four serum samples tested in Figure 5, No. 244 (A), No.150 (B), No. 158 (C),
No. 164 (D) and three new HCV+/HCC + serum samples, No. 595 (E), No. 657 (F), 679 (G), and a HCV+/HCC- serum sample, No. 643 (H), are
shown. (I) Quantitative results of the third-designed chip. Others are shown same as Figure 6.
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antigenic proteins on chips. This method allows the de-
tection of differences in relative levels of the four HCC
autoantibodies in each serum sample. It was found that
the HSP70 C-terminal domain is highly detectable by
IgG in HCV infected HCC patient sera, and HCV posi-
tive sera, but not HCV negative/HCC negative sera.
This study showed that the denaturation of antigenic
proteins improved the detection by increasing the avai-
lability of antigenic determinants on the immobilized pro-
teins, especially in the GFP section of the fusion protein.
The reproducible detection of GFP in GFP-HSP70 fusion
protein spots, enabled the increased specificity of HSP70
detection. This method is expected to be essential to set up
of diagnostic systems using multiple autoantibodies among
many sera samples. Exposure of antigenic determinants
along the whole length of the test antigen molecules may
give benefits to increase the specific antibody detection
sensitivity in this type of analysis. The authors also specu-
late that the 2-ME in the pre-treatment solution blocked
the background of maleimide residues remaining on the
chip surface and increased detection specificity. These
methods were possible because of the capacity of DLCchips to undergo heat pre-treatment and also stably, cova-
lently bind antigens [23].
It was found that many HCC antigen-positive patient
sera reacted with GFP. Such GFP-reacting sera reacted
with some GFP-fused antigens but not all. All recombi-
nant antigen proteins used in this study were fused with
GFP, so if non-specific GFP binding occurred, the
Alexa633 and Alexa555 fluorescence intensities from all
the spots should have been proportional. There were in
fact a few such cases, and these were not included in the
analysis (described in Methods). More importantly,
healthy and HCV-/HCC- sera never reacted with GFP.
The non-specific binding to GFP in some HCV+/HCC +
and HCV+/HCC- sera was reduced through the modifi-
cation of both the protein-immobilization process and
detection process in this manuscript. The remaining
reactivity of autoanitbodies in some HCC patient sera
needs to be studied further.
Conclusions
The protein chip described here is different from other
chips for its capability of antigen denaturing on chip, and
so it could be used for efficient detection of antibodies.
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high-throughput screening of sera.
Methods
Preparation of recombinant antigen proteins
Coding DNA sequences for human HSP70.1 (Gene
bank No. NM_005345), SOD2 transcript variant 2
(NM_001024465), and PRDX6 (NM_004905) genes
were cloned from human liver QUICK-Clone cDNA
(Clontech TaKaRa-bio, Shiga, Japan) by PCR. These
PCR fragments were then amplified using a primer set
containing a XhoI restriction enzyme site at the 5′-end
and a KpnI restriction site at the 3′-end to generate the
N-terminal half (ATPase domain, amino acids 1–381)
and the C-terminal half (substrate-binding domain,
amino acids 382–640) of HSP70.1, full-length matured
(signal peptide-processed) SOD2, and full-length PRDX6.
These DNA fragments were inserted into the XhoI-KpnI
sites of a 6×His-enhanced green fluorescent protein
(GFP)-5×Cys-modified pET-14b plasmid to express the
protein of interest with six tandem histidine residues and
enhanced GFP at the N-terminus and five tandem cysteine
residues at the C-terminus [23]. All plasmid constructs
were made in Escherichia coli JM109 or DH5α using
standard methods. PCR-amplified DNA fragments were
verified by DNA sequencing.
Escherichia coli BL21 strains were transformed with
newly constructed expression plasmids and the original
6×His-GFP-5×Cys plasmid (control). An inducible GFP
clone was cultured in 200 mL of Overnight Express
Medium (Novagen, Merck, Darmstadt, Germany) at 28°C
with vigorous shaking. The bacterial pellets were lysed
using BugBuster Protein Extract Reagent (Novagen) and
Benzonase (Novagen). Recombinant proteins were batch-
purified with 4 mL of HIS-Select Nickel Affinity Gel
(Sigma-Aldrich, St. Louis, MO, USA) according to the
manufacturer’s instructions except that they were washed
with Econo-Column (Bio-Rad, Hercules, CA, USA) in
phosphate-buffered saline (PBS, 6.4 mM Na2HPO4,
1.5 mM KH2PO4, 138 mM NaCl, 2.7 mM KCl, pH 7.4).
The protein-bound Nickel-Gel beads were stored in ali-
quots at −80°C in an equal volume of 1:1 Tris-buffered
saline (TBS, 10 mM Tris, 150 mM NaCl, pH 7.5) /50%
glycerol.
After thawing, recombinant proteins were eluted from
the Nickel-Gel beads with 250 mM imidazole/PBS. Buffer
was exchanged with PBS by repeated dilution and con-
centration using a Microcon YM-10 filtration column
(Millipore, Billerica, MA, USA). Protein levels and quality
were assessed by Lowry protein assay and SDS-PAGE.
Production of the protein chips
Proteins were diluted to 25.6 μmol/mL (0.796-1.87 mg/mL)
in PBS and prepared for immobilization as describedpreviously [23]. Each protein solution was printed on 3 ×
3 mm maleimide-coated DLC substrate (Toyo Kohan,
Tokyo, Japan) as an array of six lines, each with five (GFP)
or six (other proteins) 200 μm spots of 10 nL (128 fmol;
3.98-9.35 ng) using an array spotter SPBIO2000 (Hitachi
Solutions, Tokyo, Japan). The first designed chip was incu-
bated overnight, and the second and third designed chips
were incubated for 1 hr in the dark in a humidified chamber
at room temperature and then washed three times with
PBS. Protein chips were stored in PBS at 4°C in the dark
and used immediately or within 6 months. In the second de-
sign of the protein chip (Figures 6 and 7), two spots of
mouse IgG, rabbit IgG, and human IgG (Sigma-Aldrich, 64
fmol each in PBS) were immobilized on the chip in addition
to the other proteins from the first chip.
For certification of immobilized proteins, after the de-
naturation of the chips described later, specific mouse
monoclonal antibody for anti-6×His (MBL, Nagoya,
Japan, 1:500 diluted, Figure 2C), and anti-MnSOD (BD,
Franklin Lakes, NJ, USA, 1:1000, Figure 6C), or rabbit
polyclonal antibodies for anti-HSP70 (Stressgen, Victoria
BC, Canada, 1:500, Figures 2E and 6B), anti-MnSOD
(Abcam, Cambridge, UK, 1:500, Figure 2F), and anti-
peroxiredoxin 6 (Abcam, 1:500 in Figure 2G, 1:1000 in
Figure 6D) were used and washed five times with TBS-T,
then incubated for 1 hr with 1:500 diluted Alexa Fluor 633
(Alexa633)-conjugated anti-mouse or Alexa555-conjugated
rabbit IgG antibody (both Invitrogen Life Technologies,
Carlsbad, CA, USA, depending on the first antibodies),
washed with TBS-T and PBS, same as the chips incubated
with human sera.
Serum samples
Serum samples (n = 46) from patients and healthy volun-
teers were collected at Yamaguchi University Hospital.
The HCV antibody positivity of sera was analyzed with
ARCHITECT (Abbott Laboratories, Abbott Park, IL,
USA) at Yamaguchi University Hospital. The experimental
protocol was reviewed and approved by the Institutional
Review Board of Yamaguchi University Hospital (No.
H21-91-2). Sera were diluted 5- fold (the first and
second chips) or 10-fold (the third chips) with blocking
solution (5% BSA in TBS containing 0.1% Tween-20
and 0.02% NaN3).
Autoantibody detection by the protein chip
Chip detection is summarized in Figure 1A. Antigen-
bound chips were washed with PBS for 5 min, placed in a
24-well plate, and washed with 0.5 ml TBS/0.1% Tween-20
(TBS-T) for 10 min. Chips were transferred to PCR tubes
containing 200 μL of SDS/2ME sample buffer (2% SDS in
50 mM Tris–HCl (pH 6.8) with 5% 2-mercaptoethanol,
10% glycerol, and 0.0012% Bromophenol Blue), heated at
95°C for 5 min, washed five times in TBS-T, and incubated
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Chips were incubated in serum diluted five- (the first and
second chips) or ten-fold (the third chips) in 50 μL
blocking solution in a 96-well plate for 1.5 h with gentle
shaking. Chips were then incubated for 30 min with 50 μL
1:500 (the first and second chips) or 1:5000 (the third
chips) diluted anti-GFP mouse monoclonal antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) in
blocking solution. Chips were washed five times with
TBS-T, incubated for 30 min with 1:500 Alexa Fluor
633 (Alexa633)-conjugated anti-human IgG antibody
(Invitrogen, Life Technologies), followed by 30 min
adding same volume of 1:500 Alexa Fluor 555(Alexa555)-
conjugated anti-mouse IgG antibody (Invitrogen). Then
chips were washed five times with TBS-T and once with
PBS. All chips were placed on a slide holder, and mounted
with PBS and a cover slip for image analysis.
Image analysis and quantification of the chips
Fluorescent images of the first-designed chip were ob-
served under BZ-9000 fluorescent microscope (KEYENCE,
Osaka, Japan) and quantified by a microarray reader
ProScanArray (PerkinElmer, Waltham, MA, USA) at
90% laser power for both of Alexa555 and Alexa633
fluorescence using Cy3 and Cy5 detection channels,
respectively. Alexa555 and Alexa633 intensities were
quantified mainly under gain 50% and gain 90%, respec-
tively. For the chips containing spots showing strong
Alexa633 intensity, each spot was detected again under
gain 80%, and its 90% value was calculated from the li-
near relationship of gain between the 80% and 90%
values (y = 2.305× - 123.62). For the chips having spots
presenting less than 1000 pixels of Alexa555 intensity at
gain 50%, the chip spots were detected again at gain
60%, and the 50% gain values were calculated from the
linear relationship of gain between the 60% and 50%
values (y = 0.276× + 3.1268). Quantitative fluorescence
intensity data was collected after confirming that laser
power was constant using a GEO plate (PerkinElmer).
Following fluorescence detection, chips were stored for
1–12 months in sterile PBS at 4°C in the dark. For the
quantification from the second- and third-designed pro-
tein chip in Figures 6 and 7, fluorescent images of each
spot on chip were quantified by a microarray scanner
GenePix 4000B (Molecular Devices, Sunnyvale, CA, USA)
at 100% laser power using wave 532 and wave 635 channel
under PMT gain 300–800. The quantified data of F635
median-B635 (auto-antibody signal) and F532 median-
B532 (GFP antibody signal as total protein amount) from
not-saturated images of spots on the same chip, typically
1000–20000 pixels, were used for further calculation.
Quantification of autoantibody binding amounts each
spot for were calculated as follows. Autoantibody/ spot
(%) = (intensity of autoantibody signal normalized byintensity of control human IgG spot as 1/ intensity of
GFP antibody signal normalized by intensity of control
mouse IgG spot as 1) × 100. It is showing percentage of
autoantibody-bounded proteins in total immobilized pro-
teins in each spot, using normalization by human and
mouse IgG control spot.
A total of eight sera among the 42 sera tested in Figure 5
(1–3 sera in each serum group) showed high fluorescence
intensity for both Alexa555 and Alexa633; these samples
were thus excluded from the analyses, resulting in a total
of 34 serum samples analyzed in Figure 5.
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